Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-312

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
The text describes a chart (Figure 1) that shows the probability of achieving a systolic blood pressure of less than 140 mmHg after 8 weeks of treatment with a combination of Valsartan and Hydrochlorothiazide at a dose of 320 mg/25 mg. The chart includes baseline SBP readings ranging from 145 to 180 mmHg. The text also includes some medication dosages for Valsartan and Hydrochlorothiazide, as well as a blood pressure reading of 96 mmHg at the start of the study.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
The text describes a figure (Figure 2) that shows the probability of achieving a diastolic blood pressure below 90 mmHg at week 8. The figure includes measurements of baseline DBP in mmHg, ranging from 95 to 105, and a value of 100.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
This is a graphic showing the probability of achieving systolic blood pressure less than 130 mmHg at week 8 using Valsartan and Hydrochlorothiazide drugs with respective doses of 320mg and 25mg. The placebo was also included in the study. The baseline SBP (mmHg) ranges from 140 to 180. No further information is available in the given text.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
This text appears to be a medical report for a study on the effectiveness of Valsartan and Hydrochlorothiazide in lowering diastolic blood pressure. The study evaluated a dose of 320mg/25mg and showed the probability of achieving diastolic blood pressure <80mmHg at week 8. The graph shows the baseline DBP at mmHg and the probability percentage.*
FDA Label Image

Valsartan 160mg/12.5mg (Valhyctz Fig5)

Valsartan 160mg/12.5mg (Valhyctz Fig5)
This is a description of a medicine that contains Valsartan HCTZ 160mg / 12.5mg. It comes in a package of 30 dark red colored, ovaloid, biconvex, film-coated tablets with beveled edges. Each tablet is debossed with "I" on one side and "62" on the other. It is made by Aurobindo Pharma Limited, Hyderabad, India and has a product ID of PV031230. The medicine is RX only and must be stored at 20°-25°C (68°-77°F) and kept out of the reach of children. The lot number is 00000, and the expiration date is 00/00/00. The NDC number is 63187-312-30, and it is packaged by Proficient Rx LP in Thousand Oaks, CA.*
FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Valsartan Chemical Structure (Valhyctz Str1)
FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.